Please assess the completion status of the following clinical trial:

Trial Title: 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven organ confined transitional cell carcinoma (TCC) of the bladder~  * Must have undergone radical cystectomy and bilateral pelvic lymphadenectomy with pathologic stage from definitive cystectomy specimen of P1, P2a, or P2b and N0, M0 TCC with or without squamous/glandular differentiation (no adenocarcinoma, squamous cell carcinoma, or small cell carcinoma)~    * Margins must be negative for invasive or in situ TCC~   * In situ TCC in the urethra or ureter(s) allowed provided margins are negative~ * Clinical stage T1, T2a, or T2b based on transurethral resection bladder tumor specimen with P0 or PIS and N0, M0 TCC allowed~ * Incidental pT2a (Gleason score no greater than 7), pT2b (Gleason score no greater than 7), or pT2c (Gleason score no greater than 7) adenocarcinoma of the prostate allowed~* No invasive tumor into ureter(s) or urethra~* Must have potentially curable disease~* Must register within 9 weeks after surgery~* No metastatic disease by physical exam and chest x-ray or CT scan of the chest~* Eligible for randomization if:~  * p53 gene alteration present~ * Randomization occurs within 10 weeks after surgery~ * Those who are randomized to receive (MVAC) methotrexate, vinblastine, doxorubicin, and cisplatin begin MVAC within 12 weeks after cystectomy~ * No metastatic disease by physical exam and chest x-ray or CT scan of the chest~ * No prohibitive medical risk for chemotherapy~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* ECOG 0-1 OR~* Karnofsky 70-100%~Life expectancy~* Not specified~Hematopoietic~* WBC at least 4,000/mm\^3~* Platelet count at least 150,000/mm\^3~Hepatic~* SGOT or SGPT no greater than 2 times normal~* Alkaline phosphatase no greater than 2 times normal~* Bilirubin normal~Renal~* Creatinine no greater than 1.8 mg/dL OR~* Creatinine clearance at least 50 mL/min~* Blood urea nitrogen normal~Cardiovascular~* No serious arrhythmias~* No congestive heart disease with New York Heart Association class III or IV status~* Randomization group:~  * Ejection fraction must be at least 50% by MUGA scan if there is a clinical concern regarding the patient's cardiac status~Other~* No other malignancy (including synchronous papillary or invasive upper urinary tract malignancy) within the past 5 years except incidental prostate cancer (found at cystectomy), basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix~* No concurrent advanced medical illness or psychologic disease~* No prohibitive medical risk for chemotherapy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* No prior systemic chemotherapy for bladder cancer~* At least 5 years since other prior systemic chemotherapy~* Prior intravesical therapy allowed~* Randomization group:~  * Prior intravesical therapy allowed if administered prior to cystectomy~Endocrine therapy~* Not specified~Radiotherapy~* No prior pelvic irradiation~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I: M-VAC x 3 (Type: EXPERIMENTAL): Patients with altered (+) p53, reconsented to randomization, randomized to three cycles of MVAC
- Arm II: Observation (Type: NO_INTERVENTION): Patients with altered (+) p53, reconsented to randomization, randomized to observation
- Arm III: Observation (Type: NO_INTERVENTION): Patients with unaltered (-) p53
- Arm IV: Observation (Type: NO_INTERVENTION): Patients with altered (+) p53, patients did not consent to randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).